NEW YORK, July 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding The Cooper Companies Inc. (NYSE: COO), Agenus Inc. (NASDAQ: AGEN), Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT), Cell Therapeutics, Inc. (NASDAQ: CTIC) and ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4446-100free.
--
The Cooper Companies Inc. Analyst Notes
On June 30, 2014, The Cooper Companies, Inc. (Cooper) announced that it has entered into a definitive agreement for the acquisition of Sauflon Pharmaceuticals Ltd, a European manufacturer and distributor of soft contact lenses and solutions. Robert S. Weiss, Cooper's President and CEO commented, "CooperVision will now be able to offer a multi-tier daily strategy that includes a full suite of silicone hydrogel and hydrogel lenses, including options within all categories -- spheres, torics and multifocals. The daily segment is the fastest growing segment of the soft contact lens market and this transaction positions CooperVision as the premier company in this space." The transaction is valued at approximately $1.2 billion and is anticipated to close prior to FY 2014 (period ending October 31, 2014). The full analyst notes on Cooper are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/COO/report.pdf
--
Agenus Inc. Analyst Notes
On July 1, 2014, Agenus Inc. (Agenus) announced results from a single-arm, multi-institutional, open-label, Phase II study. The results showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. According to the study, 50% of the patients lived for two years, an encouraging result for a cancer that often kills patients within one year. "We believe that Prophage may play an important role in changing the treatment paradigm for patients with GBM," said Garo Armen, PhD, CEO and Chairman of Agenus. "We are exploring partnerships for Phase III studies of Prophage in GBM. Additionally, we are excited about the potential combinations of Prophage with PD-1 antagonists and other checkpoint modulators in GBM." The full analyst notes on Agenus are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/AGEN/report.pdf
--
Transcept Pharmaceuticals, Inc. Analyst Notes
On July 1, 2014, Transcept Pharmaceuticals, Inc. (Transcept) announced that it has signed a merger agreement with Paratek Pharmaceuticals, Inc (Paratek). Under the terms of the agreement, the operations of Transcept and Paratek will be combined. Glenn Oclassen, CEO and Chairman of the Transcept Board, commented, "Following Transcept's recent June 3, 2014 special cash dividend of approximately $25.4 million, this transaction with Paratek reflects the continued commitment of Transcept's Board of Directors and management team to deliver value to Transcept's stockholders. Under the proposed transaction, Transcept's stockholders will maintain a meaningful equity ownership stake in Transcept, which will refocus its operations as a late-stage therapeutics company with product candidates we believe possess significant commercial potential. The transaction also provides for our stockholders an additional special cash dividend and the opportunity to realize any upside potential from our INTERMEZZO and TO-2070 assets." The full analyst notes on Transcept are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/TSPT/report.pdf
--
Cell Therapeutics, Inc. Analyst Notes
On July 1, 2014, CTI BioPharma Corp. (CTI) announced the recruitment completion in the PERSIST-1 pivotal Phase III clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor, being evaluated for the treatment of myelofibrosis. "Completing recruitment in the PERSIST-1 trial is a significant milestone in our development program for pacritinib, and we look forward to reporting top-line results in early 2015," said James A. Bianco, M.D., President and CEO of CTI. "The high physician and patient interest in participating in this trial underscores the need for new, effective and less toxic treatment options for patients with myelofibrosis." The PERSIST-1 trial is a randomized, open-label, multicenter trial comparing the efficacy and safety of pacritinib with that of best available therapy, other than JAK inhibitors, in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, without exclusion for low platelet counts. The full analyst notes on CTI are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/CTIC/report.pdf
--
ANI Pharmaceuticals, Inc. Analyst Notes
On July 1, 2014, ANI Pharmaceuticals, Inc. (ANI) announced that it has acquired the NDA for Lithobid from Noven Therapeutics, LLC. The transaction was valued at $12 million including an $11 million upfront payment and a $1 million future milestone payment. Arthur S. Przybyl, ANI's President and CEO commented, "We are excited to add Lithobid® to our portfolio of mature brand products. Prior to the acquisition, ANI contract manufactured Lithobid®, which allows us to immediately launch ANI-labeled product. This transaction represents our second mature brand acquisition and underscores our strategy of augmenting internal generic product development efforts with acquisitions and partnerships for late stage ANDA products and mature brands." ANI is expected to launch Lithobid® in July 2014 under its own label. The full analyst notes on ANI are available to download free of charge at:
http://www.analystsreview.com/Jul-04-2014/ANIP/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
